A Closer Look At Korian's (EPA:KORI) Uninspiring ROE

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. We'll use ROE to examine Korian (EPA:KORI), by way of a worked example.

Over the last twelve months Korian has recorded a ROE of 4.9%. That means that for every €1 worth of shareholders' equity, it generated €0.05 in profit.

View our latest analysis for Korian

Advertisement

How Do I Calculate ROE?

The formula for ROE is:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

Or for Korian:

4.9% = €122m ÷ €2.5b (Based on the trailing twelve months to June 2019.)

It's easy to understand the 'net profit' part of that equation, but 'shareholders' equity' requires further explanation. It is all earnings retained by the company, plus any capital paid in by shareholders. You can calculate shareholders' equity by subtracting the company's total liabilities from its total assets.

What Does Return On Equity Signify?

ROE looks at the amount a company earns relative to the money it has kept within the business. The 'return' is the yearly profit. The higher the ROE, the more profit the company is making. So, as a general rule, a high ROE is a good thing. That means ROE can be used to compare two businesses.

Does Korian Have A Good ROE?

Arguably the easiest way to assess company's ROE is to compare it with the average in its industry. Importantly, this is far from a perfect measure, because companies differ significantly within the same industry classification. As is clear from the image below, Korian has a lower ROE than the average (7.8%) in the Healthcare industry.

ENXTPA:KORI Past Revenue and Net Income, December 24th 2019
ENXTPA:KORI Past Revenue and Net Income, December 24th 2019

That certainly isn't ideal. We'd prefer see an ROE above the industry average, but it might not matter if the company is undervalued. Nonetheless, it might be wise to check if insiders have been selling.

Why You Should Consider Debt When Looking At ROE

Virtually all companies need money to invest in the business, to grow profits. That cash can come from issuing shares, retained earnings, or debt. In the first two cases, the ROE will capture this use of capital to grow. In the latter case, the debt required for growth will boost returns, but will not impact the shareholders' equity. That will make the ROE look better than if no debt was used.

Combining Korian's Debt And Its 4.9% Return On Equity

It's worth noting the significant use of debt by Korian, leading to its debt to equity ratio of 1.11. While the ROE isn't too bad, it would probably be a lot lower if the company was forced to reduce debt. Debt increases risk and reduces options for the company in the future, so you generally want to see some good returns from using it.

The Key Takeaway

Return on equity is useful for comparing the quality of different businesses. In my book the highest quality companies have high return on equity, despite low debt. If two companies have the same ROE, then I would generally prefer the one with less debt.

But ROE is just one piece of a bigger puzzle, since high quality businesses often trade on high multiples of earnings. It is important to consider other factors, such as future profit growth -- and how much investment is required going forward. So you might want to take a peek at this data-rich interactive graph of forecasts for the company.

Of course Korian may not be the best stock to buy. So you may wish to see this free collection of other companies that have high ROE and low debt.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

About ENXTPA:CLARI

Clariane

Provides care homes, healthcare facilities and services, and shared living solutions in France, Germany, Benelux, Italy, Spain, and the United Kingdom.

Undervalued with moderate growth potential.

Advertisement

Weekly Picks

LO
Lou_Basenese
CUE logo
Lou_Basenese on Cue Biopharma ·

Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market

Fair Value:US$7065.0% undervalued
43 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
HA
HarishPK
ADBE logo
HarishPK on Adobe ·

Adobe: A Probabilistic Case for Undervaluation

Fair Value:US$319.9636.2% undervalued
46 users have followed this narrative
8 users have commented on this narrative
16 users have liked this narrative
NI
niteco
AVGO logo
niteco on Broadcom ·

A Capital Allocation Favorite with Structural Importance

Fair Value:US$651.0541.3% undervalued
45 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
TO
Tokyo
OKTA logo
Tokyo on Okta ·

Good foundation, but now it's all about the next steps

Fair Value:US$15123.0% undervalued
91 users have followed this narrative
7 users have commented on this narrative
11 users have liked this narrative

Updated Narratives

RO
RockeTeller
IVR logo
RockeTeller on Investigator Silver ·

Investigator Silver, Leverage Exposed: $1/oz Move = $42M Cash for This ASX Developer

Fair Value:AU$2.3997.7% undervalued
13 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative
TA
Talos
VOYG logo
Talos on Voyager Technologies ·

The "Landlord of Orbit" – A Deep Value Play Ahead of the Starlab Era

Fair Value:US$385.289.3% undervalued
17 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
TA
Talos
AMD logo
Talos on Advanced Micro Devices ·

The "David vs. Goliath" AI Trade – Why Second Place is Worth Billions

Fair Value:US$907.3243.6% undervalued
36 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7446.4% undervalued
66 users have followed this narrative
0 users have commented on this narrative
16 users have liked this narrative
CL
Clive_Thompson
TTWO logo
Clive_Thompson on Take-Two Interactive Software ·

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026

Fair Value:US$276.9723.5% undervalued
58 users have followed this narrative
0 users have commented on this narrative
14 users have liked this narrative
NI
niteco
HON logo
niteco on Honeywell International ·

Honeywell - The Demand-Side of the AI Infrastructure

Fair Value:US$320.1931.2% undervalued
51 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative